Drug Trial Radar · NCT02453893
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: May 27, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
288
Planned (sponsor's estimate)
Start
Nov 2013
Primary completion
Jun 2015
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
Conditions
- Schizophrenia
Interventions
IloperidoneDrug
RisperidoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- the score of Positive and Negative syndrome scale to evaluation the severity of schizophreniaTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.